While treatments like IVF and IUI remain central to fertility care, GLP-1 receptor agonists have entered the discussion as a potential new tool, especially for patients with PCOS, insulin resistance, or weight-related fertility concerns
Combined with the increased lipolysis (fat breakdown) and thermogenesis (fat burning), the net effect on body composition is more favorable than what either GLP-1 or GIP agonism can produce alone
Ros stock price has increased up to 5 points over the past weekend since the launch of the campaign
Doctor consultations An initial asynchronous consultation is included
Wegovy and Saxenda, both injectables, are the only GLP-1s FDA-approved for obesity
The following two graphs show the effects of shorter periods between doses, using half the indicated dose